Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immediate and long-term effects of orbitofrontal cortex stimulation on EEG microstates in schizophrenia.

Translational psychiatry·2026
Same author

Microbiota-metabolome interplay in depression: Metabolic insights and diagnostic potential.

Cell reports. Medicine·2026
Same author

Magnetic seizure therapy preserves delayed memory and 40-Hz auditory steady-state responses compared with electroconvulsive therapy in schizophrenia.

Schizophrenia research·2026
Same author

Cytokine changes in clinical high risk for psychosis population following antipsychotic medication.

Translational psychiatry·2026
Same author

Orbitofrontal rTMS modulates inferior parietal lobule functional reorganization to alleviate negative symptoms in first-episode, drug-naïve patients with schizophrenia.

Progress in neuro-psychopharmacology & biological psychiatry·2025
Same author

Mature NK-cell lymphoma presenting with chylothorax and delirium: a rare emergency case.

International journal of emergency medicine·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Videos

Sulpiride augmentation for schizophrenia.

Jijun Wang1, Ichiro M Omori, Mark Fenton

  • 1Department of EEG Source Imaging, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China, 200030.

The Cochrane Database of Systematic Reviews
|January 22, 2010
PubMed
Summary
This summary is machine-generated.

Sulpiride augmentation of clozapine may improve outcomes for treatment-resistant schizophrenia. While showing potential benefits like reduced appetite loss, it also increased movement disorders and prolactin levels, necessitating further research.

Related Experiment Videos

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Trials and Evidence-Based Medicine
  • Schizophrenia Treatment Research

Background:

  • Augmentation strategies are explored for antipsychotic-resistant schizophrenia.
  • Sulpiride is investigated as an add-on therapy to enhance treatment effectiveness.

Purpose of the Study:

  • To assess the efficacy and safety of sulpiride augmentation versus monotherapy in schizophrenia patients.
  • To compare sulpiride plus clozapine with clozapine alone in resistant schizophrenia.

Main Methods:

  • Systematic review of randomized clinical trials (RCTs) identified through comprehensive database searches.
  • Data extraction and analysis using fixed-effect models for dichotomous and continuous outcomes.
  • Included studies focused on treatment-resistant schizophrenia or prominent negative symptoms.

Main Results:

  • Short-term data suggested sulpiride augmentation may improve global state, reduce hypersalivation, weight gain, appetite loss, and abdominal distension.
  • However, sulpiride plus clozapine was associated with increased movement disorders and serum prolactin levels.
  • Long-term data showed no significant differences in global state or relapse rates.

Conclusions:

  • Sulpiride augmentation of clozapine shows potential for clinical improvement in specific schizophrenia cases.
  • The observed benefits are counterbalanced by adverse effects, particularly movement disorders.
  • More high-quality research is required to confirm these findings and establish optimal use.